Astellas Pharma
Tracked across 3 events · 53 articles · First seen Apr 20, 2026 · Last active Jun 30, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Regulatory
Impact: Astellas Pharma is one of the few mid-sized drug companies that confirmed its application to the United States — Medicaid pilot program, viewing it as a constructive path forward in a complex policy environment.
Apr 20, 2026 · 6 articles
Regulatory
Impact: Astellas Pharma is the manufacturer of the reference listed drug Xtandi Tablets, to which Lupin (company)'s Enzalutamide Tablets were found bioequivalent. This approval could introduce competition for Astellas Pharma's product.
Jun 26, 2026 · 16 articles
Business
Impact: Astellas Pharma's stock declined, showing a negative performance.
May 21, 2026 · 31 articles
60
Astellas Pharma applied for program United States — MedicaidTrump's Medicaid Drug Price Pilot
ERGEN INTELLIGENCE
Track Astellas Pharma live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard